Day 3 Recap: Fall Clinical 2025

To stay informed with the latest conference insights, follow us on social media and subscribe to receive our eNewsletters.

Socioeconomic Status Shapes Access to Advanced Psoriasis Therapies

New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.

Navigating Biologics and JAK Inhibitors with James Del Rosso, DO

Emerging skin treatments present unique clinical challenges that must be anticipated by clinicians.

From 30 Tips to 3 Key Insights from 3 Experts

Discover essential dermatology insights from experts at the Fall Clinical Conference 2025, featuring innovative treatment tips and patient care strategies.

Exploring the OX40 Ligand Pathway and Chronic Itch

At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”

Christopher Bunick, MD, PhD, Highlights JAK Inhibitors in AD Care

Clinicians are now aiming for treatment targets such as NRS 0–1, IGA 0–1, and EASI 90 to define successful AD management.

Our editors are on site and ready to gather your insights, both as a presenter or as an attendee! Reach out to us at DTEditor@mmhgroup.com for the opportunity to speak with one of our editors. Stay tuned to Dermatology Times all weekend for exclusive conference coverage and expert insights.